Trials / Withdrawn
WithdrawnNCT04434118
Anti-rheumatic Drug Use and Risk of COVID-19 Infection in Rheumatoid Arthritis Patients
Anti-rheumatic Drug Use and Risk of COVID-19 Infection in Rheumatoid Arthritis Patients: A Retrospective, Case-control Study
- Status
- Withdrawn
- Phase
- —
- Study type
- Observational
- Enrollment
- 0 (actual)
- Sponsor
- Sadat City University · Academic / Other
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
Rheumatoid arthritis (RA) patients have an underlying immune deficiency and typically treated with immunosuppressive drugs, which may increase the risk of COVID-19 infection. Hydroxychloroquine (HCQ) has been found to possess antiviral activity against COVID-19. Thus, the aim of this study to investigate the ability of HCQ to reduce the risk of COVID-19 among RA patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Traditional antirheumatic drugs | Hydroxychloroqine, Methotrexate, Glucocorticoids, Leflunomide, and Sulphasalazine |
Timeline
- Start date
- 2020-03-20
- Primary completion
- 2021-12-30
- Completion
- 2021-12-30
- First posted
- 2020-06-16
- Last updated
- 2022-05-09
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT04434118. Inclusion in this directory is not an endorsement.